ACR on Air Podcast
ACR on Air seeks to have informative conversations rheumatology professionals want to hear – ranging in topic from trends in clinical practice, to issues affecting rheumatology professionals, and the changing landscape of the rheumatology field. Tune in bi-weekly for new interviews and commentary that are sure to empower listeners to excel in their specialty.
Podcast Host
Our host, Jonathan Hausmann, MD, is a pediatric and adult rheumatologist at Massachusetts General Hospital and Boston Children’s Hospital. He is also an Assistant Professor of Medicine at Harvard Medical School. His research interests include autoinflammatory diseases, health technology, and medical education. Connect with Dr. Hausmann on Twitter (@hausmannMD).
Episodes
New episodes will be available twice a month on Tuesdays.
Episode 124 – 50 Years of Pediatric Rheumatology: A Retrospective
Episode 123 – VEXAS Syndrome: What You Need to Know
Episode 122 – Support for Private Practice
Episode 121 – Pericardial Diseases in Rheumatology & Beyond
Episode 120 – Current and Evolving Treatments for Myositis
Browse previous episodes in the ACR on Air archive.
Episode Show Notes
Fifty years ago, pediatric rheumatic disease was often marked by disability, limited treatment options, and low expectations for long-term outcomes. In 1976, a small group of clinicians and scientists helped launch a new understanding of immune-mediated disease in children and laid the foundation for modern pediatric rheumatology. In this episode, we explore how the field evolved from managing chronic disability to expecting remission, transforming both treatment and quality of life for children. We also examine the scientific breakthroughs, models of care, and remaining challenges that continue to shape the future of pediatric rheumatology.
Ekemini Ogbu, MD, MSc – Ekemini Ogbu, MD, MSc, is a pediatric rheumatologist and physician-scientist. She is an Associate Professor of Pediatric Rheumatology at Cincinnati Children’s Hospital Medical Center (CCHMC)/University of Cincinnati. She is the Director of Neuroinflammatory Disease Services in Rheumatology at CCHMC and Co-Director of the Cincinnati Children's Lupus Center. She conducts clinical and translational research in childhood-onset systemic lupus. Dr. Ogbu is the chair of the American College of Rheumatology Committee on Pediatric Rheumatology.
Don’t forget to like, share, and subscribe!
Today, we discuss a new guidance statement from the American College of Rheumatology aimed at bringing much-needed structure to the evaluation and management of patients with VEXAS. This episode breaks down key recommendations, including who should be tested, the best approaches to diagnostic evaluation, how to interpret bone marrow findings, and emerging strategies for treatment—offering clarity in a diagnosis that, until recently, was marked by uncertainty.
Arsene Mekinian, MD, PhD – Arsene Mekinian, MD, PhD, is a Professor of Immunology, Rheumatology, and Internal Medicine at Sorbonne University and a clinician in the Internal Medicine Department at Saint Antoine Hospital in Paris. He earned his medical degree from Paris Descartes University and a PhD in Immunology from Sorbonne University. His clinical expertise spans autoimmune diseases in pregnancy and fertility, including recurrent pregnancy loss and unexplained obstetrical complications, as well as rheumatologic and systemic autoimmune conditions such as lupus and rheumatoid arthritis. He also has a strong focus on rare immunohematological disorders, including VEXAS syndrome and immune thrombocytopenia. His research centers on autoimmune systemic diseases, particularly systemic sclerosis and Takayasu arteritis, and he serves as president of the French MINHEMON and International VEXAS Groups within the CEREMAIAA network. With over 360 scientific publications and an active international presence, Dr. Mekinian is also the founder and president of Santé Armenie, an Armenian-French medical NGO dedicated to advancing healthcare access.
Related Links:
Don’t forget to like, share, and subscribe!
Private rheumatology practice is contracting under multi-directional pressure: shrinking margins, escalating prior authorizations, tightening Pharmacy Benefit Managers (PBM) and payer restrictions on drug access, and instability across core revenue streams. At the same time, demand is rising, wait times are surging, and workforce shortages are intensifying—driving clinician burnout and retention challenges.
This episode is about the American College of Rheumatology’s response, in expanding its leadership role in advocacy, health policy reform, and workforce development to help private practices move from survival to sustainable growth.
Nehad Soloman, MD, FACR – Nehad Soloman, MD, FACR, is one of the managing partners at Arizona Arthritis & Rheumatology Associates, P.C., and serves as the Chief Medical Officer and Medical Director of research. He has recently served on the ACR Board of Directors and has participated in a number of initiatives with ACR, including the Committee on Workforce and Training, CORC and CPC. He has gone to Washington, DC with the ACR to advocate on behalf of patients and physicians alike. He has also been past president of the Phoenix Rheumatology Association. He is a recipient of numerous academic accolades and is well published.
Don’t forget to like, share, and subscribe!
Pericardial Disease is couched between two medical disciplines: Cardiology and Rheumatology, and those with these conditions visit medical professionals viewing their treatment through one lens or the other. This episode addresses the shifting reality that pericarditis and myocarditis are no longer separate silos but rather takes the broader view of inflammatory heart disease. We’ll examine how rheumatologists should be thinking about pericardial disease, when we should get involved, how diagnosis and imaging fit in, plus the evolution of treatment.
Dor Lotan, MD – Dor Lotan, MD, is an Assistant Professor of Medicine at Columbia University Irving Medical Center and NewYork-Presbyterian in New York. He is an advanced heart failure cardiologist with specialized expertise in heart transplantation, mechanical circulatory support, cardiogenic shock, and cardio-rheumatology.
Dr. Lotan founded and serves as Medical Director of the Center for Pericardial and Myocardial Diseases at Columbia University Medical Center, where he developed a multidisciplinary program that brings together rheumatology, cardiology, advanced imaging, and cardiac surgery to care for patients with inflammatory heart disease. The Columbia program is recognized among the leading centers in the United States for pericardial diseases and has been acknowledged by the American Heart Association Pericarditis Initiative as one of the top sites in the country.
Dr. Lotan has focused on pericardial disease for more than a decade, beginning with close collaboration with global leaders in the field. He has authored numerous papers and book chapters, participated in clinical trials, and served as an international principal investigator to help advance the field of pericardial disease. He is internationally recognized and frequently invited to lecture and educate the next generation of clinicians on pericardial diseases.
In addition, Dr. Lotan serves as Medical Director of the Centralized Heart Failure Management Program across NewYork-Presbyterian. He is also a Director of the Myocarditis Foundation, helping advance awareness and research in myocarditis, and serves as an Associate Editor for Circulation: Heart Failure Journal.
Don’t forget to like, share, and subscribe!
For years, myositis treatment has relied on broad immune suppression with drugs like steroids, methotrexate, and rituximab—but what if we could target the disease more precisely? Inflammatory myopathies are not a single condition, but a group of biologically distinct syndromes with different clinical features and immune pathways. As our understanding evolves, so does the potential for more personalized, targeted therapies. In this episode, we’re joined by Julie J. Paik, MD, MHS, to discuss how this shift could reshape the future of myositis treatment.
Julie J. Paik, MD, MHS – Julie J. Paik, MD, MHS, is an Associate Professor of Medicine in the Division of Rheumatology. She completed her undergraduate degree at the Johns Hopkins University and medical degree at George Washington University School of Medicine. Thereafter, Dr. Paik pursued her internal medicine residency at UCLA-Cedars-Sinai/West LA VA medical center, where she served an additional year as chief resident. She then completed fellowship training in rheumatology at Johns Hopkins and then transitioned to the faculty.
Dr. Paik’s clinical and research interests are focused on neuromuscular manifestations of autoimmune diseases, particularly in the areas of myositis and scleroderma. To fortify her methodologic strengths during fellowship training and advance her research interests, Dr. Paik completed a Masters in Clinical Investigation at the Johns Hopkins Bloomberg School of Public Health.
The focus of Dr. Paik’s current research efforts is in determining the mechanisms of muscle disease in scleroderma. Whereas her clinical practice is focused on the broad range of autoimmune and inflammatory muscle disease in rheumatology, there is a particular emphasis on the neuromuscular manifestations of scleroderma.
Don’t forget to like, share, and subscribe!